Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec;45(6):616-621.
doi: 10.1111/1753-6405.13155. Epub 2021 Nov 11.

The utility of SARS-CoV-2-specific serology in COVID-19 diagnosis

Tasnim Hasan  1 , H Ling Lim  1 , Jennifer Case  2 , Linda Hueston  1 , Shopna Bag  3 , Dominic E Dwyer  1 , Matthew V N O'Sullivan  1
Affiliations

The utility of SARS-CoV-2-specific serology in COVID-19 diagnosis

Tasnim Hasan et al. Aust N Z J Public Health. 2021 Dec.

Abstract

Introduction: In May 2020, The Communicable Diseases Network of Australia (CDNA) case definition introduced serological criteria to support the diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We present findings that support the utility of SARS-CoV-2-specific serology for public health investigations.

Methods: From 24 January to 31 July 2020, the following information was collected from individuals with positive SARS-CoV-2-specific immunofluorescence antibody tests: history of contact with COVID-19 cases; recent travel; symptoms consistent with COVID-19; and SARS-CoV-2 nucleic acid testing (NAT) results. Individuals were classified as confirmed or probable by CDNA criteria or additionally as possible (SARS-CoV-2-specific IgG positive with compatible symptoms or epidemiologic risk) or indeterminate (SARS-CoV-2-specific IgA/IgM positive only) cases.

Results: A total of 10,595 individuals were tested in the six-month period. Of these, 9.8% (1,037) individuals had positive SARS-CoV-2-specific serology of which 566 (53.6%) were NAT-confirmed COVID-19 cases and 286 (27.6%) were part of a cruise ship outbreak sero-survey. The remaining 185 individuals (NAT negative) were individually classified as serologically confirmed (4, 0.4%), probable (72, 6.9%) possible (66, 6.4%) and indeterminate (38, 3.7%) cases. Maternal antibody transfer was inferred in one infant and four were unclassified.

Conclusion: SARS-CoV-2-specific serology is a key diagnostic tool for retrospective identification of COVID-19 infection. Implications for public health: SARS-CoV-2 specific serology can enhance the ability to find cases, link missing cases in clusters of infection and identify the epidemiological extent of SARS-CoV-2 outbreaks. A combination of epidemiological criteria, clinical criteria and a quantitative serological test can be used as an adjunct to classify SARS-CoV-2 cases. Our study confirms the low level of community transmission in NSW during the first year of the COVID-19 pandemic.

Keywords: case definitions; covid-19; serology.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Breakdown of positive serology performed by NSW Health Pathology January to July 2020.
Figure 2
Figure 2
Classification of 185 SARS‐CoV‐2 sero‐positive individuals.
See this image and copyright information in PMC

References

    1. NSW Ministry of Health . State Government of New South Wales; Sydney (AUST): 2020. COVID‐19 Cases by Date and Likely Source of Infection [Internet]Available from: https://data.nsw.gov.au/data/dataset/nsw-covid-19-cases-... [cited 2020 Nov].
    1. Australian Department of Health . Government of Australia; Canberra (AUST): 2020. Coronavirus (COVID‐19) at a Glance – 1 July 2020 [Internet]Available from: https://www.health.gov.au/sites/default/files/documents/... [cited 2020 Aug].
    1. Australian Department of Health COVID‐19, Australia: Epidemiology report 19 (Fortnightly reporting period ending June 21, 2020) Commun Dis Intell (2018) 2020;44 - PubMed
    1. McAnulty JM, Ward K. Suppressing the epidemic in New South Wales. N Engl J Med. 2020;382(21):e74. - PMC - PubMed
    1. Gidding H, Machalek D, Hendry A, Quinn H, Vette K, Beard F, et al. Seroprevalence of SARS‐CoV‐2‐specific antibodies in Sydney, Australia following the first epidemic wave in 2020. Med J Aust. 2021;214(4):179–185. - PMC - PubMed

Substances